Sarepta Therapeutics
SRPT
457 hedge funds and large institutions have $10.8B invested in Sarepta Therapeutics in 2024 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 173 increasing their positions, 155 reducing their positions, and 81 closing their positions.
26% more call options, than puts
Call options by funds: $278M | Put options by funds: $221M
12% more repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 155
2.8% less ownership
Funds ownership: 93.92% → 91.12% (-2.8%)
5% less funds holding
Funds holding: 483 → 457 (-26)
23% less capital invested
Capital invested by funds: $14B → $10.8B (-$3.19B)
30% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 81
50% less funds holding in top 10
Funds holding in top 10: 16 → 8 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$268M |
| 2 |
BlackRock
New York
|
+$96.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$91.9M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$86.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$75.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$231M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$222M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$150M |
| 4 |
Jane Street
New York
|
-$114M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$86.4M |
SRPT Hedge Fund Activity: Q3 2024 in Review
457 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2024, worth a combined $10.8B — down 23% from $14B a quarter earlier.
Sellers outnumbered buyers: 81 funds closed out of SRPT and 57 opened new positions — a net loss of 24 holders — while 155 trimmed existing stakes and 173 added.
The largest buyer was Capital International Investors, adding an estimated $268M. The largest seller was Morgan Stanley, cutting an estimated $231M.
- 457 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2024, down from 483 in Q2 2024.
- Funds reported $10.8B of Sarepta Therapeutics stock for Q3 2024, down 23% quarter-over-quarter.
- 57 funds opened new Sarepta Therapeutics positions in Q3 2024 and 81 closed out, a net change of -24 holders.
- The largest Sarepta Therapeutics buyer in Q3 2024 was Capital International Investors, an estimated $268M added.
- The largest Sarepta Therapeutics seller in Q3 2024 was Morgan Stanley, an estimated $231M sold.
Based on aggregated 13F filings for Q3 2024.